Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 10/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.50 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SI | P14410 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757405 | 1.00 | CYP4Z1 (0.50) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL9346882 | 0.83 | CYP4Z1 (0.50) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL1757403 | 0.83 | CYP4Z1 (0.50) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL14359614 | 0.80 | CYP4Z1 (0.48) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL6388692 | 0.80 | CYP4Z1 (0.58) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL5851764 | 0.79 | CYP4Z1 (0.57) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL4866578 | 0.79 | CYP4Z1 (0.53) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL28547818 | 0.79 | CYP4Z1 (0.44) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL4865106 | 0.78 | CYP4Z1 (0.52) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL16639135 | 0.76 | CYP4Z1 (0.55) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368642-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-3555104-A1 | NRF2 COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109646-A1 | NRF2 COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5955487-A | TREATING HIGH BLOOD PRESSURE, CARDIAC INSUFFICIENCY, GLAUCOMA | CIBA-GEIGY CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| WO-1997030036-A1 | ARYL DERIVATIVES | NOVARTIS AG (CH) | 1997-08-21 | — | — | WO | disclosed |
| US-5644055-A | Antihypertensive tricyclic azepine derivatives useful as inhibitors of enkephalinase and ACE | CIBA-GEIGY CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| US-5620998-A | CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0706525-A1 | ANTIHYPERTENSIVE TRICYCLIC AZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | Novartis AG (CH) | 1996-04-17 | — | — | EP | disclosed |
| US-5506240-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1995001353-A1 | ANTIHYPERTENSIVE TRICYCLIC AZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | CIBA-GEIGY AG (CH) | 1995-01-12 | — | — | WO | disclosed |
| US-5369110-A | Hypotensive agents, cardiac insufficiency treatment | CIBA-GEIGY CORPORATION (US) | 1994-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | CYP4Z1 3216/4885CYP1A2 3861/4885CYP2C8 4154/4885 |
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | CYP4Z1 4320/4885CYP1A2 3682/4885CYP2C8 1783/4885 |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | CFB, TFPI, MAOB | CYP4Z1 2224/4885CYP1A2 181/4885CYP2C8 301/4885 |
| US-20250368642-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | CYP4Z1 3309/4885CYP1A2 3374/4885CYP2C8 2036/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | CYP4Z1 3216/4885CYP1A2 3861/4885CYP2C8 4154/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | CYP4Z1 550/4885CYP1A2 465/4885CYP2C8 373/4885 |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CYP4Z1 4677/4885CYP1A2 4753/4885CYP2C8 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.